Nexium OTC Switch Would Face Crowded Field, Potential Questions
This article was originally published in The Tan Sheet
Executive Summary
Pfizer will pay AstraZeneca $250 million upfront for global rights to market a potential OTC 20-mg Nexium. Pharma marketing expert Joe McGovern expects Nexium “to start OTC with a big bang,” but Center for Consumer Self Care Executive Director Bill Soller points to potential safety questions about a switch.
You may also be interested in...
UK Nexium Ad Rapped For Downplaying Treatment For Persistent Heartburn
Pfizer’s TV ad for Nexium Control short-term heartburn treatment implied consumers with persistent heartburn need not seek professional medical advice, UK Advertising Standards Authority says. Pfizer argued that information in the ad was in line with MHRA's approval for the drug’s indications and packaging warned consumers not to use more than 14 days.
Orally Dissolving Competition Lurks For Prevacid 24HR, Other OTC PPIs
While GSK Consumer Healthcare's latest ad campaign for Prevacid 24HR features "Lurker," a fireball character who educates consumers on the risk of recurrence of heartburn, oral disintegration of an active ingredient is the latest differentiator in the OTC PPI category.
Orally Dissolving Competition Lurks For Prevacid 24HR, Other OTC PPIs
While GSK Consumer Healthcare's latest ad campaign for Prevacid 24HR features "Lurker," a fireball character who educates consumers on the risk of recurrence of heartburn, oral disintegration of an active ingredient is the latest differentiator in the OTC PPI category.